ARTICLE | Management Tracks
Neurocrine’s Gorman to retire as CEO
Plus: Eisner becomes CMO of Vir and updates from Entact, Gates Medical Research Institute, Compass, Armonica and Omega
May 30, 2024 12:12 AM UTC
Kevin Gorman will retire as CEO of Neurocrine Biosciences Inc. (NASDAQ:NBIX) in October while joining the neuro company’s board. Chief Business Development and Strategy Officer Kyle Gano will succeed him in the top spot. Neurocrine, which Gorman founded in 1992, markets Ingrezza valbenazine to treat tardive dyskinesia and chorea associated with Huntington disease.
Vir Biotechnology Inc. (NASDAQ:VIR) hired Mark Eisner as EVP and CMO, effective June 3. Eisner was CMO at Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA). Former CMO Phil Pang left the company in March. ...